$TWST

Leproust Emily M. sold $158K of TWST

Leproust Emily M. (Chief Executive Officer) sold 2,265 shares of Twist Bioscience Corp (TWST) at $69.84 ($0.16M total) on 2026-06-08.

Original reporting
SEC EDGAR · Leproust Emily M.
Published Jun 10, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 10, 2026, 8:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TWST
Neutral
medium confidence
Mentioned
$TWST
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTNeutralLow
01

Why it matters

The only new information is the reported open-market sale size, price, and post-transaction holdings; it may marginally influence sentiment but does not change company fundamentals on its own.

02

Market read

Traders may monitor TWST for follow-on insider activity, but this single modest sale is unlikely to drive a durable repricing without additional catalysts.

03

What to watch

The filing notes no pre-arranged 10b5-1 plan; however, absence of a stated plan does not prove information trading—context (other sales, compensation, tax events) is not provided.

Relevance 4/10Novelty 8/10Timing: Filed 2026-06-10 (covers sale dated 2026-06-08)

Background

The article is an SEC Form 4 insider transaction disclosure for Twist Bioscience CEO Emily M. Leproust.

Company-level read

Ticker impact

$TWSTNeutralMedium confidence
Context

CEO Emily M. Leproust filed an open-market sale of 2,265 TWST shares for about $158.2K on 2026-06-08 (Form 4).

Expected impact

Likely limited near-term impact; treat as a small sentiment signal rather than a fundamental catalyst.

Evidence & confidence

Form 4 insider sales are typically low-signal unless paired with unusual size, acceleration, or accompanying corporate/regulatory developments; this disclosure is modest in value and does not indicate a new business event.

Market effects

No direct sector read-through; this is company-specific insider transaction data.

None.

None.

Counterpoint

Insider sales can be planned for diversification/taxes and may not reflect bearish fundamentals, especially when not tied to a corporate event.

Key entities

  • Twist Bioscience Corp

    Subject of the Form 4 insider sale disclosure.

  • Emily M. Leproust

    CEO and director who sold 2,265 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TWSTHigh

Twist Bioscience Stock Jumps On Lilly AI Drug Discovery Deal

Twist Bioscience (TWST) stock rose 9.74% after announcing a deal with Eli Lilly for AI-driven drug discovery. The company reported $118.4M in Q3 revenue, up 23% YoY, with improved gross margins. TWST remains unprofitable but expects adjusted EBITDA breakeven in Q4. The Lilly partnership validates its technology and business model, according to the company.

$TWSTHighAI 8/10

Twist Bioscience Stock Jumps As Lilly AI Deal Lifts Outlook

Twist Bioscience (TWST) stock rose 9.94% after announcing a deal with Eli Lilly to supply data for its AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year guidance to $456–457M. UBS initiated coverage with a Neutral rating and $144 price target. TWST is targeting adjusted EBITDA breakeven in Q4 FY26.

$TWSTMedAI 8/10

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Growth Story

Twist Bioscience (TWST) stock rose 9.94% after reporting Q3 FY26 revenue of $118.4M, up 23% YoY, and raising full-year guidance to $456–$457M. The company announced an AI collaboration with Eli Lilly, boosting its valuation. TWST has 14 consecutive quarters of growth, 52.8% gross margin, and targets adjusted EBITDA breakeven in Q4 FY26.

$TWSTHighAI 8/10

Twist Bioscience TWST Stock Jumps On Lilly AI Deal

Twist Bioscience (TWST) stock rose 11.43% after announcing a deal with Eli Lilly to provide antibody characterization data for Lilly's AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year revenue guidance to $456–457M. UBS initiated coverage with a Neutral rating and a $144 price target.